Subcutaneous formulation off to an encouraging start; R&D pipeline progressing well
13/08/20 -"Despite being slightly impacted by COVID-19 in Q2, Darzalex continued to gain share in the multiple myeloma market. Given the encouraging launch of the subcutaneous formulation, we anticipate a ..."
Pages
62
Language
English
Published on
13/08/20
You may also be interested by these reports :
17/09/20
Since our last Teaser in May 2019, it has been a rollercoaster ride for Grifols (Buy, Spain), a leading player in the $23bn oligopolistic plasma ...
17/09/20
Merck confirmed our positive view on the company. As expected, management confirmed the FY 2022 guidance and put some nice colour on 2021. The ...
09/09/20
In line with its strategy of expanding its focus on the immuno-oncology space and strengthening its internal R&D pipeline, Sanofi has spent €5.2bn on ...
07/09/20
Surprisingly, Akebia’s oral HIF-PHI drug, Vadadustat, has shown heart safety concerns in a phase III study for non-dialysis CKD-anaemic patients. ...